Small Molecules
29 December 2013
Lundbeck receives European marketing authorization for Brintellix for the treatment of adults with Major Depressive Episodes27 December 2013
Takeda Announces Termination of Fasiglifam (TAK-875) Development25 December 2013
Synergy Pharmaceuticals Closes Enrollment for Plecanatide Phase 2b Trial in Patients with IBS-C23 December 2013
GSK and MMV announce FDA Breakthrough Therapy designation for tafenoquine for Plasmodium vivax malaria23 December 2013
Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis23 December 2013
RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Stud23 December 2013
Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus21 December 2013
Actelion is granted Marketing Authorisation for Opsumit (macitentan) in Pulmonary Arterial Hypertension (PAH) by the European Commission21 December 2013
FDA Approves Orenitram(TM) (treprostinil) Extended-Release Tablets for the Treatment of Pulmonary Arterial Hypertension21 December 2013
ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias20 December 2013
Ultragenyx Announces Results From Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy20 December 2013
BioCryst Files Peramivir NDA for the Treatment of Influenza19 December 2013
BeiGene Enrolls First Patient in Phase 1 Study of BGB-28319 December 2013
Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation19 December 2013
ANORO(TM) ELLIPTA(TM) Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the US18 December 2013
BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors for Hereditary Angioedema into Preclinical Development18 December 2013
Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study17 December 2013
Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation17 December 2013
RedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori InfectionNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports